On September 25, according to foreign media Endpoints, Johnson & Johnson is closing its cardiovascular and metabolic drug division.An informed source stated that the decision mainly affects the sales, marketing, and medical affairs teams, which were notified on Wednesday (9.25). A Johnson & Johnson spokesperson said in a statement, "We must adapt and evolve our business in a complex and rapidly changing external environment."This is Johnson & Johnson's second major restructuring after closing the Infectious Diseases and Vaccines division last year. During the previous restructuring, Johnson & Johnson implemented layoffs globally and divested many vaccine and prevention programs. This round of restructuring primarily impacts the commercial operations of the cardiovascular division rather than research and development.A year ago, Johnson & Johnson renamed its pharmaceutical division from Janssen Pharmaceuticals to Johnson & Johnson Innovative Pharmaceuticals (J&J Innovative Medicine), Johnson & Johnson has been downplaying cardiovascular and metabolic drug work since then. As part of the change, Johnson & Johnson narrowed its R&D focus to three therapeutic areas: oncology, immunology, and neuroscience.Johnson & Johnson'sCardiac TubeAnd MetabolismMedicineThe core product of the department is Xarelto (Rivaroxaban). Rivaroxaban, developed in collaboration between Johnson & Johnson and Bayer, was once one of the best-selling drugs in the world.In August this year,According to the United StatesThe Inflation Reduction Act (IRA)）》，BayerTopbeIncluded in the list of the first 10 drugs required to undergo Medicare price negotiations. The U.S. government negotiated a 62% reduction in the drug's price, but this does not include the cost after rebates or discounts.According to Johnson & Johnson's financial report, the global sales of Xarelto in the first half of 2024 were $1.105 billion, a year-on-year decrease of 9.1%. Bayer reportedGlobal XareltoSales were $1.83 billion, a year-over-year decrease of 4.8%.Johnson & Johnson has also collaborated with BMS to develop the next-generation anticoagulant milvexian, which is currently in Phase III clinical trials for the treatment of atrial fibrillation and secondary prevention of stroke."We remain committed to the development of milvexian," a spokesperson said.Copyright © 2024 PHARMCUBE. All Rights Reserved.
Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position;For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.
Disclaimer: The information in this WeChat article is for general reference only and should not be used directly as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.
↑Click to scan the QR code and go directly to the live broadcast room↑
